IVIM Health vs MEDVi: November 2026 prices compared
As of November 20, 2026, neither IVIM Health nor MEDVi printed a month-to-month compounded price that applies at the maintenance dose, so this page compares what each did show and how each bills, without a price verdict.
Released · Last reviewed · how we verify
IVIM Health and MEDVi, measure by measure
| Measure | IVIM Health | MEDVi |
|---|---|---|
| Tirzepatide, month to month | from $192 (per month, starting-dose price) | — |
| Tirzepatide, lowest printed | $192 ($117 + $75 program fee) | — |
| Semaglutide, month to month | from $140 (per month, starting-dose price) | — |
| Semaglutide, lowest printed | $140 ($65 + $75 program fee) | — |
| Dose pricing | priced by dose or not stated | not confirmed |
| Membership or program fee | about $75 a month | not confirmed |
| Computed score | 8 of 40 (position 18 of 27) | 0 of 40 (position 21 of 27) |
| FDA warning letters | 721816 (2026-02-20) | 721455 (2026-02-20) |
| November 20 read | first-party read | not readable Nov 20 |
Strengths and limitations: which fits whom
IVIM Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. MEDVi cannot be judged on price this month because its page could not be read on November 20, 2026. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| IVIM Health | tirzepatide | — | from $192 |
| IVIM Health | semaglutide | — | from $140 |
Regulatory record
FDA’s warning-letter index lists warning letter 721816 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to IVIM Health; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 721455 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to MEDVi; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, IVIM Health or MEDVi?
Neither printed a comparable month-to-month price on November 20, 2026, so there is no like-for-like answer this month.
Do IVIM Health and MEDVi charge a membership fee?
IVIM Health: about $75 a month on top of medication; MEDVi: not confirmed on November 20, 2026. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are IVIM Health and MEDVi medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- IVIM Health pricing page (read November 20, 2026)
- MEDVi pricing page (not readable on November 20, 2026)
- FDA warning letter 721816 to IVIM Health (dated 2026-02-20, posted 2026-03-03)
- FDA warning letter 721455 to MEDVi (dated 2026-02-20, posted 2026-03-03)